Format

Send to

Choose Destination
Thorax. 2017 Nov;72(Suppl 2):ii1-ii64. doi: 10.1136/thoraxjnl-2017-210927.

British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).

Author information

1
Cambridge Centre for Lung Infection, Papworth Hospital, Cambridge, UK.
2
Abertawe Bro Morgannwg University Health Board, Princess of Wales Hospital, Bridgend, UK.
3
Pharmacy Department, St James's University Hospital, Leeds, UK.
4
Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, UK.
5
Manchester Royal Infirmary, Manchester, UK.
6
Scottish Mycobacteria Reference Laboratory, Royal Infirmary of Edinburgh, Edinburgh, UK.
7
Department of Respiratory Medicine, Western General Hospital. Edinburgh, UK.
8
Host Defence Unit, Royal Brompton Hospital, and National, Heart and Lung Institute, Imperial College, London, UK.
9
Department of Respiratory Medicine, Guys and St Thomas NHS Foundation Trust, London, UK.
10
British Thoracic Society, London UK.
11
Division of Infection, Immunity & Respiratory Medicine, University of Manchester, Wythenshawe Hospital, Manchester, UK.
12
Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
13
North Bristol Lung Centre, Southmead Hospital, Bristol, UK.
14
Queen Alexandra Hospital, Portsmouth, UK.
15
Department of Medicine, University of Cambridge, UK.
PMID:
29054853
DOI:
10.1136/thoraxjnl-2017-210927
[Indexed for MEDLINE]

Conflict of interest statement

Competing interests: JB has received honorarium funding from AZ. TC has received funding from Chiesi. AF has received funding from GSK. ARF has received funding from Insmed. CSH has received funding from Aradigm, Chiesi, Gilead, Insmed, Raptor, Teva, Vertex, Zambon. ML has received funding from Insmed, Pulmocide, Bayer, Chiesi and Raptor. RW has received funding from Bayer.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center